Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Massachusetts Financial Services Co. MA dramatically increased its stake in Gilead, buying an additional 4,113,999 shares in Q4 (a 3,763.8% increase) and now holds 4,223,304 shares worth about $518.4 million (~0.34% of the company).
• Gilead recently beat quarterly estimates (EPS $1.86 vs. $1.83; revenue $7.93B vs. $7.68B), set FY2026 guidance of 8.45–8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.4% yield).
• The company is accelerating its oncology push—agreeing to acquire Tubulis for up to $5 billion and licensing KT‑200 (triggering a $45M milestone)—while analysts remain mostly bullish (consensus target ~$156.42) but show some divergence, including a notable $115 target from Cantor Fitzgerald.

Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3,763.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,223,304 shares of the biopharmaceutical company's stock after purchasing an additional 4,113,999 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.34% of Gilead Sciences worth $518,368,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares during the last quarter. Legal & General Group Plc boosted its stake in Gilead Sciences by 4.2% in the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company's stock valued at $1,133,376,000 after acquiring an additional 414,454 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Gilead Sciences by 5.9% in the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company's stock valued at $793,506,000 after acquiring an additional 400,002 shares during the last quarter. Nordea Investment Management AB boosted its stake in Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company's stock valued at $630,056,000 after acquiring an additional 726,101 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in Gilead Sciences by 46.7% in the third quarter. Los Angeles Capital Management LLC now owns 3,845,379 shares of the biopharmaceutical company's stock valued at $426,837,000 after acquiring an additional 1,223,895 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $139.03 on Friday. The company's 50 day moving average is $145.13 and its 200-day moving average is $130.47. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a market cap of $172.56 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The company's quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences's payout ratio is presently 48.45%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider owned 131,779 shares of the company's stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 299,280 shares of company stock worth $42,820,550. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Daiwa Securities Group boosted their target price on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. Citigroup reiterated a "buy" rating on shares of Gilead Sciences in a research note on Friday, March 6th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Finally, Truist Financial boosted their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $156.42.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.